## [Kidney Disease](/us-en/patients-and-caregivers/diseases/kidney-disease "Kidney Disease") Building on a 40-year legacy that began in transplant, Novartis is on a mission to empower breakthroughs and transform care in kidney health, starting with kidney conditions that have significant unmet need. Historically, these conditions have had considerably less funding and research, leading to a treatment landscape largely focused on reactive or end-stage disease management, often with significant physical, emotional, and financial burdens. Our goal is to help patients living with kidney diseases by partnering with patients, advocates, clinicians, and policymakers to raise awareness, accelerate diagnosis, and get patients the care they need, sooner. ## Areas of Focus - [IgAN](#tabigan-29516) - [C3G](#tabc3g-29521) Immunoglobulin A nephropathy (IgAN) is a progressive, rare kidney disease in which the immune system damages the kidneys, often causing glomerular inflammation and proteinuria.1,2 With almost 13 out of every million people in the United States diagnosed per year, it is one of the most common primary autoimmune kidney diseases, and each person’s journey is unique.2,3 Up to 50% of IgAN patients progress to kidney failure within 10 to 20 years of diagnosis, often requiring maintenance dialysis and/or kidney transplantation.3-7 C3 glomerulopathy (C3G) is a progressive and ultra-rare kidney disease with the average age of diagnosis around 23 years old.8-10 Prognosis is poor, with approximately half of people living with C3G progressing to kidney failure within 10 years of diagnosis, requiring lifelong dialysis and/or kidney transplantation.8,11 ![Actor portrayal ](/us-en/sites/novartis_us/files/styles/cta_image/public/2026-01/image%20%2811%29.png.webp?itok=0IqHx3Dp "Smiling woman Gisela’s Story") ## Gisela’s Story: New Hope for Treating Inflammatory Diseases of the Kidney Novartis researchers aim to preserve kidney function for patients. [Learn more](https://www.novartis.com/stories/new-hope-treating-inflammatory-diseases-kidney "Learn more") ## Our Pipeline [Learn more](https://www.novartis.com/research-development/novartis-pipeline?search_api_fulltext=&field_therapeutic_area%5B%5D=2936) ## Additional Resources [ ### Products ](/us-en/node/33006) [ ### Clinical Trials ](https://www.novartis.com/clinicaltrials/study) [ ### Investigative Clinical Trials ](https://www.novartis.com/healthcare-professionals/investigator-initiated-trials-studies-clinical-and-investigator-initiated-research-non-clinical) ## Other Therapeutic Areas [ ![Two women smiling as they walk together through a sunny park, enjoying a friendly moment. ](/us-en/sites/novartis_us/files/styles/cards_1_3/public/2025-10/two-women-smiling-as-they-walk_1.JPG.webp?itok=DY3f7H1A "Two women smiling as they walk together through a sunny park, enjoying a friendly moment. ") ### Immunology See how we are creating a world where health care professionals have more options and people living with immunological conditions can live their daily lives without limitations. ](https://www.novartis.com/us-en/about/therapeutic-areas/immunology) [ ![smiling patient and two healthcare professionals](/us-en/sites/novartis_us/files/styles/cards_1_3/public/2025-10/two-smiling-healthcare-professionals-in-a-medical-office-smiling-with-a-patient-as-they-check-his-pulse.png.jpeg.webp?itok=39Yf3l9h "smiling patient and two healthcare professionals") ### Oncology Combining the power of science and empathy to unravel the inner workings of cancer and develop innovative therapies that restore hope to those with cancer and their loved ones. ](https://www.novartis.com/us-en/about/therapeutic-areas/oncology) [ ![nurse and patient exchanging warm moment](/us-en/sites/novartis_us/files/styles/cards_1_3/public/2025-10/nurse-patient-exchanging-warm-moment.jpg.jpeg.webp?itok=o8iXY9_J "nurse and patient exchanging warm moment") ### Neuroscience Creating a transformational impact for people living with severe neurological conditions and their caregivers by discovering, developing and delivering innovative medicines that change the course of disease progression. ](https://www.novartis.com/about/therapeutic-areas/neuroscience) **References** 1. IgA nephropathy. National Institute of Diabetes and Digestive and Kidney Diseases. Accessed March 2025. 2. Kwon CS, Daniele P, Forsythe A, et al. A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin A nephropathy*. J Health Econ Outcomes Res*. 2021;8(2):36-45. [doi:10.36469/001c.26129](https://pmc.ncbi.nlm.nih.gov/articles/PMC8410133/) 3. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). *Kidney Int*. 2025;108(4):S1-S71. [doi:10.1016/j.kint.2025.04.004](https://www.kidney-international.org/article/S0085-2538(25)00279-0/fulltext) 4. Xie J, Kiryluk K, Wang W, et al. Predicting progression of IgA nephropathy: new clinical progression risk score. *PLoS One*. 2012;7(6):e38904. [doi:10.1371/journal.pone.0038904](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0038904) 5. Pitcher D, Braddon F, Hendry B, et al. Long-term outcomes in IgA nephropathy. *Clin J Am Soc Nephrol*. 2023;18(6):727-738. [doi:10.2215/CJN.0000000000000135](https://pmc.ncbi.nlm.nih.gov/articles/PMC10278810/) 6. Hastings MC, Bursac Z, Julian BA, et al. Life expectancy for patients from the Southeastern United States with IgA nephropathy. *Kidney Int Rep*. 2018;3(1):99-104. [doi:10.1016/j.ekir.2017.08.008](https://pmc.ncbi.nlm.nih.gov/articles/PMC5762959/) 7. Sim JJ, Bhandari S, Sun L, et al. ESKD and CKD progression among a diverse immunoglobulin A nephropathy (IgAN) population. Poster presented at: ASN Kidney Week 2023; November 2-5, 2023; Philadelphia, PA. Poster TH-PO615. 8. Martín B, Smith RJH. C3 glomerulopathy. In: Adam MP, Feldman J, Mirzaa GM, et al, eds. GeneReviews® \[Internet\]. University of Washington, Seattle; 1993-2025. Updated April 5, 2018. Accessed February 2025. 9. Schena FP, Esposito P, Rossini M. A narrative review on C3 glomerulopathy: a rare renal disease. *Int J Mol Sci.* 2020;21(2):525. [doi:10.3390/ijms21020525](https://pmc.ncbi.nlm.nih.gov/articles/PMC7013756/) 10. Caravaca-Fontán F, Lucientes L, Cavero T, et al. Update on C3 glomerulopathy: a complement-mediated disease. *Nephron*. 2020;144(6):272-280. [doi:10.1159/000507254](https://doi.org/10.1159/000507254) 11. Smith RJH, Appel GB, Blom AM, et al. C3 Glomerulopathy—Understanding a Rare Complement-Driven Renal Disease. *Nat Rev Nephrol*. 2019;15(3):129-143. [doi: 10.1038/s41581-018-0107-2](https://pmc.ncbi.nlm.nih.gov/articles/PMC6876298/)